Sanofi
1 year ago ⋅ English ⋅ 14 min read
Newsroom
Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this... Read More
Sanofi
1 year ago ⋅ English ⋅ 3 min read
Newsroom
Media Update: Sanofi completes closing for potential first-in-class vaccine against extraintestinal pathogenic E.coli (ExPEC)

Sanofi completes closing for potential first-in-class vaccine against extraintestinal pathogenic E. coli (ExPEC)Paris, November 9, 2023. Sanofi announces today completion of closing for... Read More
Sanofi
1 year ago ⋅ English ⋅ 3 min read
Newsroom
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results

Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 resultsQ3 2023 sales growth of 3.2% at CER and business EPS(1) decrease of 2.1% at CER- S... Read More
Sanofi
1 year ago ⋅ English ⋅ 9 min read
Newsroom
Sanofi Enters Next Chapter of Play to Win Strategy

Sanofi Enters Next Chapter of Play to Win Strategy- Increases investments in its pipeline to fully realize long-term growth potential, bolstered by successful launches and R&D progr... Read More
Sanofi
1 year ago ⋅ English ⋅ 12 min read
Newsroom
Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)- Late-breaking presentation at... Read More
Sanofi
1 year ago ⋅ English ⋅ 9 min read
Newsroom
Media Update: Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous UrticariaParis and Tarrytown, N.Y. October 20, 2023. The U.S. Food and Drug Administration... Read More